Loading clinical trials...
Loading clinical trials...
A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With Major Depressive Episodes Associated With Bipolar I Disorder
Conditions
Interventions
LB-102
Placebo
Locations
3
United States
Cenexel Hollywood Florida
Hollywood, Florida, United States
Cenexel Decatur GA
Decatur, Georgia, United States
CenExel Gaithersburg
Gaithersburg, Maryland, United States
Start Date
January 23, 2026
Primary Completion Date
February 1, 2028
Completion Date
February 1, 2028
Last Updated
April 17, 2026
NCT07540338
NCT07172516
NCT07288320
NCT07213466
NCT06804525
NCT05303064
Lead Sponsor
LB Pharmaceuticals Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions